APLN and chronic kidney disease: In conclusion, we have shown in a randomised, double-blind, placebo-controlled crossover study that apelin has beneficial systemic and renal effects in healthy subjects, and these effects are preserved and accentuated in patients with CKD already optimised on current treatment.